|
Oct 3
|
Bullish Biohaven Insiders Loaded Up On US$41.7m Of Stock
|
|
Oct 1
|
Biohaven Announces Pricing of $250 Million Public Offering of Common Shares
|
|
Sep 30
|
Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine
|
|
May 15
|
Director Gregory Bailey Acquires 15,000 Shares of Biohaven Ltd (BHVN)
|
|
May 14
|
Down -24.55% in 4 Weeks, Here's Why Biohaven Ltd. (BHVN) Looks Ripe for a Turnaround
|
|
May 13
|
Down -32.76% in 4 Weeks, Here's Why Biohaven Ltd. (BHVN) Looks Ripe for a Turnaround
|
|
May 9
|
Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments
|
|
Apr 26
|
Independent Director of Biohaven John Childs Buys 3.2% More Shares
|
|
Apr 26
|
3 Biotech Stocks to Buy on the Dip: April 2024
|
|
Apr 25
|
Director Gregory Bailey Acquires 25,503 Shares of Biohaven Ltd (BHVN)
|
|
Apr 23
|
Director Gregory Bailey Acquires 48,780 Shares of Biohaven Ltd (BHVN)
|
|
Apr 22
|
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
|
|
Apr 18
|
Biohaven Announces Pricing of $230 Million Public Offering of Common Shares
|
|
Apr 17
|
Biohaven Announces Proposed Public Offering of Common Shares
|
|
Apr 13
|
Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business Updates
|
|
Apr 4
|
LLY, REGN, BHVN: Which Biotech Stock Offers the Most Upside?
|
|
Mar 20
|
Bullish Biohaven Insiders Loaded Up On US$23.8m Of Stock
|
|
Jan 8
|
Biohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference; Established Extensive Portfolio Across 20 Therapeutic Indications in Neuroscience, Immunology and On...
|
|
Jan 2
|
Biohaven to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Dec 31
|
Director Irina Antonijevic Sells 11,000 Shares of Biohaven Ltd (BHVN)
|